New Delhi: Biotechnology company Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK.
Key Highlights
- Brand Names: The drug will be marketed as Liraglutide Biocon for diabetes and Biolide for chronic weight management.
- Regulatory Approval: The Medicines and Healthcare Products Regulatory Agency (MHRA) approved the drug earlier this year, making Biocon the first generics company to secure approval for gLiraglutide in a major regulated market.
- Global Expansion Plans: Biocon aims to expand the drug’s reach into other European markets, the US, and select geographies.
About Liraglutide
Liraglutide is a Glucagon-like peptide-1 (GLP-1) analog, which helps lower blood sugar levels and aids in weight loss. It is administered as a once-daily injection.
Market Impact
Despite the launch, Biocon’s shares saw a 3.17% decline, trading at ₹302.15 per share on the BSE.
